Related Experiment Videos
[Phase II clinical trials in patients with lung cancer]
Abstract:
The goal of phase II clinical trials is to determine whether a new drug has activity against particular cancers. This trial, therefore, is the most important study in the process of development of investigational new agents and frequently may give misleading results. The design of phase II clinical trials of new anticancer agents in lung cancer has been reviewed based on the Guidelines for the Clinical Evaluation of Antineoplastic Agents notified by the Ministry of Health and Welfare in Japan. These guidelines present general approaches to clinical trials and should be adhered to in the development of investigational drugs in humans, although they are not directly mandated by law or regulations. We considered the policies of these guidelines and instituted them based on the actual circumstances in Japan, in order to develop a scientific and rational approach for clinical phase II trials. In addition, we introduced new active agents having a novel mechanism of action that show clinical activity in the treatment of lung cancer, such as irinotecan (CPT-11), a topoisomerase I inhibitor, and paclitaxel (taxol) and taxotere, targeting the microtubules.
Insights
Phase II clinical trials are crucial for evaluating new anticancer drugs, particularly in lung cancer. This review examines Japanese guidelines for designing these trials to ensure scientific rigor and avoid misleading results.
Area of Science:
- Oncology
- Clinical Pharmacology
- Drug Development
Background:
- Phase II clinical trials are pivotal for assessing the efficacy of investigational anticancer agents.
- These trials are critical in the drug development pipeline but can yield misleading outcomes.
- Lung cancer drug development necessitates robust phase II trial designs.
Purpose of the Study:
- To review the design of phase II clinical trials for new anticancer agents in lung cancer.
- To adapt and apply Japanese Ministry of Health and Welfare guidelines for clinical evaluations.
- To establish a scientific and rational approach for phase II trials in the Japanese context.
Main Methods:
- Review of existing guidelines for the clinical evaluation of antineoplastic agents in Japan.
- Consideration of specific policies within the Japanese regulatory and clinical environment.
- Incorporation of novel agents with distinct mechanisms of action.
Main Results:
- The study emphasizes adherence to established guidelines for developing investigational drugs.
- It highlights the importance of a scientific and rational approach tailored to local circumstances.
- Introduction of new agents like irinotecan (CPT-11), paclitaxel, and taxotere for lung cancer treatment.
Conclusions:
- Phase II trial design in lung cancer requires careful consideration of guidelines and local context.
- Adherence to scientific principles can mitigate the risk of misleading results.
- Novel agents targeting topoisomerase I and microtubules show promise in lung cancer therapy.